EUCTR2018-002109-70-CZ进行中（未招募）1 期
Early phase 2 clinical trial of E6011 in patients with active Crohn’s disease - Not applicable
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who meet all of the following criteria are eligible to participate in this clinical trial.
- •(1) Crohn’s disease patients aged 18 or over and under 65 on the date of consent.
- •(2) Patients diagnosed on basis of clinical findings, endoscopic findings, etc. with small intestine-type, small and large intestine-type, or large intestine-type Crohn's disease at least 12 weeks before giving consent.
- •(3) Patients with a baseline (at Week 0 before the start of IMP administration) disease severity ranging from moderate to severe. CDAI score between 220 and 450, and a PRO2 score between 14 and 34.
- •(4) Patients with a Simple Endoscopic Score for Crohn’s Disease (SES-CD) = 7 (or for patients with isolated ileal disease, = 4 in ileum segment) in the screening period, with one or more ulcers (in SES-CD score, ulcer presence subscore = 1 in any segment) assessed by colonoscopy and confirmed by a centralised review.
- •(5) Patients who received adrenocorticosteroids or immunomodulators in the past, but showed no therapeutic response (insufficient response) or the drugs were not tolerated (intolerance). Alternatively, patients who cannot taper adrenocorticosteroids (dependence). Alternatively, patients who showed no therapeutic response after administering biologic(s) (primary nonresponse), patients who initially showed therapeutic response but it lessened or disappeared afterwards (secondary nonresponse), or patients who did not tolerate the drug (intolerance). (Detailed criteria are described in Attachment 7 and Attachment 8).
- •(6) If the patients are taking 1,200 kcal/day or less enteral nutrition, the dosage and administration have not changed for at least 4 weeks prior to the start of the IMP administration.
- •(7) If the patients are taking aminosalicylic acid (5-ASA), salazosulfapyridine, or antibiotics for the treatment of Crohn's disease (metronidazole, ciprofloxacin, etc.), the dosage and administration have not changed for at least 4 weeks prior to the start of the IMP administration.
- •(8) If the patients are taking under 30 mg/day of oral prednisolone (or equivalent adrenocorticosteroid) or 9 mg/day or less of oral budesonide, the dosage and administration have not changed for at least 4 weeks prior to the start of the IMP administration.
- •(9) If the patients are taking azathioprine (AZP), 6-mercaptopurine (6-MP) or methotrexate (MTX), the dosage and administration have not changed for at least 8 weeks prior to the start of the IMP administration.
- •(10) Patients who have received a sufficient explanation about the compliance rules of this clinical trial, who are willing to comply with them, and who are able to do so.
- •(11) Patients who voluntarily gave a written consent to participate in this clinical trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients diagnosed with ulcerative colitis or indeterminate colitis
- •Patients diagnosed with gastrointestinal epithelial dysplasia
- •Patients who have an abscess or are suspected to have one
- •Patients with an artificial anus, ileo-anal pouch or fistula
- •Patients with symptomatic or high-grade gastrointestinal stenosis
- •Patients who, after undergoing small bowel resection, have been diagnosed with a short bowel syndrome, which makes maintaining caloric intake difficult
- •Patients who have newly started seton drainage treatment within 12 weeks prior to the start of the IMP
- •Patients who have undergone bowel resection or a gastrointestinal surgery within 24 weeks prior to the start of the IMP administration
- •Patients who tested positive for C. difficile toxin test in the screening
- •Patients who tested positive for HIV, hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, hepatitis B virus DNA, hepatitis C virus antibody, or human T cell leukemia virus type 1 antibody in the screening
- •Patients with positive or repeated indeterminate results on the TB test
- •Patients with findings showing a history of tuberculosis on a chest X-ray test in the screening period
- •Patients with findings of neurological symptoms such as motor impairment, cognitive disorder, language disorder or dysphagia in the evaluations during the screening period
- •Patients with a WBC count of less than 3,000/µL or blood CD4+ cell count under 200/µL in the screening tests
- •Patients with a medical history of clinically significant vasculitis
- •Acute myocardial infarction, unstable angina pectoris, cerebral infarction, and symptomatic cerebral haemorrhage patients
- •Patients whose AST or ALT was more than three times the UNL in the screening period tests or patients whose serum creatinine level was more than 1.5 times the UNL in the screening tests
- •Patients with a QTcF exceeding 450 ms repeatedly in standard 12-lead ECG tests in the screening period tests
- •Patients who have undergone cytoapheresis (granulocytapheresis) within 2 weeks prior to the start of the IMP
- •Hospitalisation within 4 weeks prior to the start of IMP, intravenous treatment of antibiotics, antiviral drugs within 4 weeks prior to the start of IMP or oral treatment of antibiotics, antiviral drugs within 2 weeks prior to the start of IMP. COVID-19: patients required hospitalization within 4 weeks prior to the start of the IMP, any intravenous treatment within 4 weeks prior to the start of the IMP or any oral treatment within 2 weeks prior to the start of IMP
- •Patients who received total parenteral nutrition, peripheral parenteral nutrition, or enteral nutrition exceeding 1200 kcal/day within 4 weeks prior to the start of the IMP
- •Patients who received =30 mg/day of oral prednisolone (or an equivalent adrenocorticosteroid), adrenocorticosteroid injection, enema or suppository within 4 weeks prior to the start of the IMP
- •Patients who received cyclosporine, mycophenolate mofetil, or tacrolimus within 8 weeks prior to the start of the IMP
- •Patients who received adalimumab, infliximab, certolizumab pegol, vedolizumab or ustekinumab within 8 weeks prior to the start of the IMP
- •Patients vaccinated with live vaccines within 12 weeks prior to the start of the IMP
- •Patients who received an immunoglobulin preparation or a blood product within 24 weeks prior to the start of the IMP administration
- •Patients who have received natalizumab or E6011 in the past
- •Patients with a history of
研究者
相似试验
进行中（未招募）
1 期
A research aimed study to test the efficacy and safety of a new medical product, called E6011, in treating Crohn’s disease, which is a type of inflammatory bowel diseaseActive Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-002109-70-HUEA Pharma Co., Ltd.40
终止
2 期
Early phase 2 clinical trial of E6011 in patients with active Crohn's diseaseCrohn's DiseaseJPRN-jRCT2080224078EA Pharma Co.,Ltd.40
未知
1 期
A Phase 1 Clinical Study of E6130 -Clinical Pharmacology Study in Healthy Adult Male SubjectsHealthy Adult SubjectsJPRN-jRCT2080223723EA Pharma Co., Ltd.44
已完成
2 期
A Study of E6011 in Participants With Active Crohn's DiseaseCrohn's DiseaseNCT03733314EA Pharma Co., Ltd.25
进行中（未招募）
1 期
A trial to investigate the use of Veregen ointment in the treatment of vulval intraepithelial neoplasia, a severe skin disorder that may lead to vulval cancer.Vulval intraepithelial neoplasia (VIN)MedDRA version: 16.1Level: LLTClassification code 10057313Term: Vulval intraepithelial neoplasia grade IIISystem Organ Class: 100000004864EUCTR2013-003107-19-GBniversity of Birmingham26